{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:03:07Z","timestamp":1791424987587,"version":"4.3.3"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In vitro evaluation of substances utilizing the putative proton\u2011coupled organic cation (H\n                      <jats:sup>+<\/jats:sup>\n                      \/OC) antiporter for active uptake across the blood-brain barrier (BBB) and brain cell membranes requires a thorough understanding of cellular pharmacokinetics supported by reliable translational readouts. This study assessed the rate and extent of uptake of the antiporter substrate oxycodone in brain endothelial and parenchymal cells at clinically relevant concentrations, exploring the suitability of various cell models for investigating active drug transport.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Transcellular transport studies were performed using primary brain endothelial cells (BECs) from pig, rat, and mouse, alongside uptake assays in immortalized human cerebral microvascular endothelial cells (hCMEC\/D3) and rat brain slices. Drug uptake was estimated by combining transport data with non-specific binding data via equilibrium dialysis. The effect of interleukin-6 (IL-6) on oxycodone uptake was tested in hCMEC\/D3 cells. The unbound intracellular-to-extracellular concentration ratio (K\n                      <jats:sub>p,uu,cell<\/jats:sub>\n                      ) and efflux ratio were used to compare the extent of net uptake across models and evaluate the presence of active uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Based on cellular pharmacokinetic parameters, both primary BECs and hCMEC\/D3 demonstrated active uptake of oxycodone. Mean permeability across primary BECs ranged between 0.9\u2009\u00d7\u200910\u207b\u2075 (pig) and 1.8\u2009\u00d7\u200910\u207b\u2075 (rat) cm\/s. Transport extent, reflected by 1\/Efflux Ratio values of 1.5 (pig) and 2.4 (rat), aligned with in vivo unbound brain-to-plasma concentration ratios, K\n                      <jats:sub>p,uu,brain<\/jats:sub>\n                      , indicating predominant active uptake. In hCMEC\/D3 cells, the uptake rate was time- and concentration-dependent within 60\u00a0min and 10\u20135000 nM concentration range, while the uptake extent, assessed by K\n                      <jats:sub>p,uu,cell<\/jats:sub>\n                      , was 1.7 and independent of both. IL-6 increased the extent of uptake to 148% of control, without affecting the rate. The extent of uptake into parenchymal cells was also concentration-independent, with K\n                      <jats:sub>p,uu,cell<\/jats:sub>\n                      values around 1.8, similar to endothelial cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings provide insight into oxycodone distribution across the BBB and into brain parenchymal cells, particularly emphasizing the contribution of probable active transport mechanisms at multiple barriers. The results highlight the importance of assessing both the rate and extent of transport and support the utility of K\n                      <jats:sub>p,uu,cell<\/jats:sub>\n                      as a key metric for comparing drug transport across models. Both primary BECs and hCMEC\/D3 cells are reliable tools for assessing substrate uptake in drug development, particularly for H\n                      <jats:sup>+<\/jats:sup>\n                      \/OC antiporter substrates, and hold translational potential for mechanistic studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-025-00726-w","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:27:29Z","timestamp":1761830849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative analysis of the uptake of the H+\/OC antiporter substrate oxycodone across and into brain endothelial and parenchymal cells with in vitro\u2013in vivo extrapolation"],"prefix":"10.1186","volume":"22","author":[{"given":"Frida","family":"B\u00e4llgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aghavni","family":"Ginosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberte Bay Villekjaer","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Schallburg","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"108283","DOI":"10.1016\/j.pharmthera.2022.108283","volume":"239","author":"A Sachkova","year":"2022","unstructured":"Sachkova A, Jensen O, D\u00fccker C, Ansari S, Brockm\u00f6ller J. The mystery of the human proton-organic cation antiporter: one transport protein or many? Pharmacol Ther. 2022;239:108283.","journal-title":"Pharmacol Ther"},{"key":"726_CR2","doi-asserted-by":"crossref","unstructured":"Kurosawa T, Tega Y, Uchida Y, Higuchi K, Tabata H, Sumiyoshi T, et al. Proteomics-Based transporter identification by the PICK method: involvement of TM7SF3 and LHFPL6 in proton-coupled organic cation antiport at the blood-brain barrier. Pharmaceutics. 2022;14(8).","DOI":"10.3390\/pharmaceutics14081683"},{"issue":"10","key":"726_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1124\/dmd.108.022087","volume":"36","author":"T Okura","year":"2008","unstructured":"Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36(10):2005\u201313.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"726_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12987-024-00544-6","volume":"21","author":"N Svane","year":"2024","unstructured":"Svane N, Pedersen ABV, Rodenberg A, Ozg\u00fcr B, Saaby L, Bundgaard C, et al. The putative proton-coupled organic cation antiporter is involved in uptake of triptans into human brain capillary endothelial cells. Fluids Barriers CNS. 2024;21(1):39.","journal-title":"Fluids Barriers CNS"},{"issue":"10","key":"726_CR5","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1002\/jps.24129","volume":"103","author":"A Kitamura","year":"2014","unstructured":"Kitamura A, Higuchi K, Okura T, Deguchi Y. Transport characteristics of Tramadol in the blood-brain barrier. J Pharm Sci. 2014;103(10):3335\u201341.","journal-title":"J Pharm Sci"},{"issue":"1","key":"726_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-8118-10-8","volume":"10","author":"K Shimomura","year":"2013","unstructured":"Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, et al. Functional expression of a proton-coupled organic cation (H+\/OC) antiporter in human brain capillary endothelial cell line hCMEC\/D3, a human blood-brain barrier model. Fluids Barriers CNS. 2013;10(1):8.","journal-title":"Fluids Barriers CNS"},{"issue":"7","key":"726_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1023\/A:1018923017954","volume":"11","author":"M Yamazaki","year":"1994","unstructured":"Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, et al. Carrier-mediated transport of H1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. Pharm Res. 1994;11(7):975\u20138.","journal-title":"Pharm Res"},{"issue":"5","key":"726_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1248\/bpb.17.676","volume":"17","author":"M Yamazaki","year":"1994","unstructured":"Yamazaki M, Fukuoka H, Nagata O, Kato H, Ito Y, Terasaki T, et al. Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994;17(5):676\u20139.","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"726_CR9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1023\/A:1018980914687","volume":"11","author":"M Yamazaki","year":"1994","unstructured":"Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, et al. Carrier-Mediated transport of H1-Antagonist at the Blood-Brain barrier: A common transport system of H1-Antagonists and lipophilic basic drugs. Pharm Res. 1994;11(11):1516\u20138.","journal-title":"Pharm Res"},{"issue":"9","key":"726_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1124\/dmd.106.009746","volume":"34","author":"E Bostr\u00f6m","year":"2006","unstructured":"Bostr\u00f6m E, Simonsson US, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics\/pharmacodynamics. Drug Metab Dispos. 2006;34(9):1624\u201331.","journal-title":"Drug Metab Dispos"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neuropharm.2017.08.002","volume":"128","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Lindstr\u00f6m V, Ingelsson M, Hammarlund-Udenaes M, Syv\u00e4nen S. Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology. Neuropharmacology. 2018;128:482\u201391.","journal-title":"Neuropharmacology"},{"issue":"11","key":"726_CR12","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s11095-023-03583-0","volume":"40","author":"F B\u00e4llgren","year":"2023","unstructured":"B\u00e4llgren F, Hammarlund-Udenaes M, Loryan I. Active uptake of oxycodone at both the Blood-Cerebrospinal fluid barrier and the Blood-Brain barrier without sex differences: A rat Microdialysis study. Pharm Res. 2023;40(11):2715\u201330.","journal-title":"Pharm Res"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12987-024-00583-z","volume":"21","author":"F B\u00e4llgren","year":"2024","unstructured":"B\u00e4llgren F, Bergfast T, Ginosyan A, Mahajan J, Lipcsey M, Hammarlund-Udenaes M, et al. Active CNS delivery of oxycodone in healthy and endotoxemic pigs. Fluids Barriers CNS. 2024;21:86.","journal-title":"Fluids Barriers CNS"},{"issue":"8","key":"726_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","volume":"25","author":"M Hammarlund-Udenaes","year":"2008","unstructured":"Hammarlund-Udenaes M, Frid\u00e9n M, Syv\u00e4nen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737\u201350.","journal-title":"Pharm Res"},{"issue":"5","key":"726_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/0271678X16630991","volume":"36","author":"HC Helms","year":"2016","unstructured":"Helms HC, Abbott NJ, Burek M, Cecchelli R, Couraud PO, Deli MA, et al. In vitro models of the blood-brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862\u201390.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"726_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","volume":"299","author":"JW Polli","year":"2001","unstructured":"Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001;299(2):620\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"726_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2019.01.015","volume":"24","author":"N Colclough","year":"2019","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, Frid\u00e9n M, McGinnity DF. Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery. Drug Discovery Today. 2019;24(5):1067\u201373.","journal-title":"Drug Discovery Today"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejpb.2021.10.006","volume":"169","author":"B Ozg\u00fcr","year":"2021","unstructured":"Ozg\u00fcr B, Saaby L, Janfelt C, Langthaler K, Eneberg E, Jacobsen AM, et al. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: in vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice. Eur J Pharm Biopharm: Official J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV. 2021;169:211\u20139.","journal-title":"Eur J Pharm Biopharm: Official J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"2","key":"726_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejpb.2012.07.020","volume":"82","author":"E Hellinger","year":"2012","unstructured":"Hellinger E, Veszelka S, Toth AE, Walter F, Kittel A, Bakk ML, et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm : Official J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV. 2012;82(2):340\u201351.","journal-title":"Eur J Pharm Biopharm : Official J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"2","key":"726_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1124\/dmd.105.007211","volume":"34","author":"A Gupta","year":"2006","unstructured":"Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of Cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metab Dispos. 2006;34(2):318\u201323.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"726_CR21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s11095-022-03246-6","volume":"39","author":"I Loryan","year":"2022","unstructured":"Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C, et al. Unbound Brain-to-Plasma partition Coefficient, K(p,uu,brain)-a game changing parameter for CNS drug discovery and development. Pharm Res. 2022;39(7):1321\u201341.","journal-title":"Pharm Res"},{"issue":"7","key":"726_CR22","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","volume":"108","author":"B Feng","year":"2019","unstructured":"Feng B, West M, Patel NC, Wager T, Hou X, Johnson J, et al. Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration. J Pharm Sci. 2019;108(7):2476\u201383.","journal-title":"J Pharm Sci"},{"issue":"9","key":"726_CR23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1124\/dmd.107.015222","volume":"35","author":"M Frid\u00e9n","year":"2007","unstructured":"Frid\u00e9n M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos. 2007;35(9):1711\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"726_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2045-8118-10-6","volume":"10","author":"I Loryan","year":"2013","unstructured":"Loryan I, Frid\u00e9n M, Hammarlund-Udenaes M. The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS. 2013;10(1):6.","journal-title":"Fluids Barriers CNS"},{"issue":"6","key":"726_CR25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1124\/dmd.108.026377","volume":"37","author":"M Frid\u00e9n","year":"2009","unstructured":"Frid\u00e9n M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37(6):1226\u201333.","journal-title":"Drug Metab Dispos"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainres.2013.04.006","volume":"1521","author":"A Patabendige","year":"2013","unstructured":"Patabendige A, Skinner RA, Morgan L, Joan Abbott N. A detailed method for Preparation of a functional and flexible blood\u2013brain barrier model using Porcine brain endothelial cells. Brain Res. 2013;1521:16\u201330.","journal-title":"Brain Res"},{"key":"726_CR27","doi-asserted-by":"crossref","unstructured":"Veszelka S, T\u00f3th A, Walter FR, T\u00f3th AE, Gr\u00f3f I, M\u00e9sz\u00e1ros M, et al. Comparison of a rat primary cell-based blood-brain barrier model with epithelial and brain endothelial cell lines: gene expression and drug transport. Front Mol Neurosci. 2018;11.","DOI":"10.3389\/fnmol.2018.00166"},{"issue":"Pt 1","key":"726_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1242\/jcs.103.1.23","volume":"103","author":"NJ Abbott","year":"1992","unstructured":"Abbott NJ, Hughes CC, Revest PA, Greenwood J. Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci. 1992;103(Pt 1):23\u201337.","journal-title":"J Cell Sci"},{"issue":"13","key":"726_CR29","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1096\/fj.04-3458fje","volume":"19","author":"BB Weksler","year":"2005","unstructured":"Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19(13):1872\u20134.","journal-title":"FASEB J"},{"issue":"1","key":"726_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2045-8118-10-16","volume":"10","author":"B Weksler","year":"2013","unstructured":"Weksler B, Romero IA, Couraud P-O. The hCMEC\/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS. 2013;10(1):16.","journal-title":"Fluids Barriers CNS"},{"issue":"5","key":"726_CR31","doi-asserted-by":"publisher","first-page":"e38149","DOI":"10.1371\/journal.pone.0038149","volume":"7","author":"E Urich","year":"2012","unstructured":"Urich E, Lazic SE, Molnos J, Wells I, Freskg\u00e5rd PO. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE. 2012;7(5):e38149.","journal-title":"PLoS ONE"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.bbih.2020.100188","volume":"10","author":"A Kawase","year":"2021","unstructured":"Kawase A, Chuma T, Irie K, Kazaoka A, Kakuno A, Matsuda N, et al. Increased penetration of diphenhydramine in brain via proton-coupled organic cation antiporter in rats with lipopolysaccharide-induced inflammation. Brain Behav Immun - Health. 2021;10:100188.","journal-title":"Brain Behav Immun - Health"},{"key":"726_CR33","doi-asserted-by":"crossref","unstructured":"B\u00e4llgren F, Hammarlund-Udenaes M, Loryan I. Reduced oxycodone brain delivery in rats due to lipopolysaccharide-induced inflammation: microdialysis insights into brain disposition and sex-specific pharmacokinetics. 2024, Submitted.","DOI":"10.1186\/s12987-024-00598-6"},{"issue":"14","key":"726_CR34","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","volume":"95","author":"S Ohshima","year":"1998","unstructured":"Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998;95(14):8222\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"726_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/09537100500163168","volume":"16","author":"M Lipcsey","year":"2005","unstructured":"Lipcsey M, Larsson A, Olovsson M, Sj\u00f6lin J, Eriksson MB. Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets. 2005;16(7):408\u201314.","journal-title":"Platelets"},{"issue":"2","key":"726_CR36","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1917","volume":"8","author":"C Gabay","year":"2006","unstructured":"Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Therapy. 2006;8(2):S3.","journal-title":"Arthritis Res Therapy"},{"issue":"2","key":"726_CR37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/jps.24691","volume":"105","author":"A Kitamura","year":"2016","unstructured":"Kitamura A, Okura T, Higuchi K, Deguchi Y. Cocktail-Dosing Microdialysis study to simultaneously assess delivery of multiple Organic-Cationic drugs to the brain. J Pharm Sci. 2016;105(2):935\u201340.","journal-title":"J Pharm Sci"},{"issue":"20","key":"726_CR38","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1111\/bph.13258","volume":"172","author":"H Chapy","year":"2015","unstructured":"Chapy H, Goracci L, Vayer P, Parmentier Y, Carrupt PA, Decl\u00e8ves X, et al. Pharmacophore-based discovery of inhibitors of a novel drug\/proton antiporter in human brain endothelial hCMEC\/D3 cell line. Br J Pharmacol. 2015;172(20):4888\u2013904.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"726_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jps.21807","volume":"99","author":"Y Nakazawa","year":"2010","unstructured":"Nakazawa Y, Okura T, Shimomura K, Terasaki T, Deguchi Y. Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect. J Pharm Sci. 2010;99(1):467\u201374.","journal-title":"J Pharm Sci"},{"issue":"1","key":"726_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12987-020-00200-9","volume":"17","author":"JA Brown","year":"2020","unstructured":"Brown JA, Faley SL, Shi Y, Hillgren KM, Sawada GA, Baker TK, et al. Advances in blood-brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure. Fluids Barriers CNS. 2020;17(1):38.","journal-title":"Fluids Barriers CNS"},{"key":"726_CR41","doi-asserted-by":"crossref","unstructured":"Kristensen M, Kucharz K, Felipe Alves Fernandes E, Str\u00f8mgaard K, Schallburg Nielsen M, Cederberg Helms HC, et al. Conjugation of therapeutic PSD-95 inhibitors to the cell-penetrating peptide tat affects blood-brain barrier adherence, uptake, and permeation. Pharmaceutics. 2020;12(7).","DOI":"10.3390\/pharmaceutics12070661"},{"key":"726_CR42","doi-asserted-by":"crossref","unstructured":"Nielsen SSE, Siupka P, Georgian A, Preston JE, T\u00f3th AE, Yusof SR, et al. Improved method for the establishment of an in vitro blood-brain barrier model based on porcine brain endothelial cells. J Vis Exp. 2017(127).","DOI":"10.3791\/56277"},{"issue":"6","key":"726_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","volume":"33","author":"R P\u00f6yhi\u00e4","year":"1992","unstructured":"P\u00f6yhi\u00e4 R, Sepp\u00e4l\u00e4 T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33(6):617\u201321.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"726_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","volume":"58","author":"M Kinnunen","year":"2019","unstructured":"Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58(6):705\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fneng.2013.00007","volume":"6","author":"AD Wong","year":"2013","unstructured":"Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC. The blood-brain barrier: an engineering perspective. Front Neuroeng. 2013;6:7.","journal-title":"Front Neuroeng"},{"issue":"3","key":"726_CR46","doi-asserted-by":"publisher","first-page":"e0236770","DOI":"10.1371\/journal.pone.0236770","volume":"16","author":"MS Thomsen","year":"2021","unstructured":"Thomsen MS, Humle N, Hede E, Moos T, Burkhart A, Thomsen LB. The blood-brain barrier studied in vitro across species. PLoS ONE. 2021;16(3):e0236770.","journal-title":"PLoS ONE"},{"issue":"19","key":"726_CR47","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1021\/jm070375w","volume":"50","author":"H Wan","year":"2007","unstructured":"Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A. High-throughput screening of drug-brain tissue binding and in Silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50(19):4606\u201315.","journal-title":"J Med Chem"},{"issue":"8","key":"726_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/bdd.325","volume":"23","author":"JC Kalvass","year":"2002","unstructured":"Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23(8):327\u201338.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"726_CR49","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1021\/mp4000822","volume":"10","author":"A Mateus","year":"2013","unstructured":"Mateus A, Matsson P, Artursson P. Rapid measurement of intracellular unbound drug concentrations. Mol Pharm. 2013;10(6):2467\u201378.","journal-title":"Mol Pharm"},{"issue":"1","key":"726_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0165-5728(95)00148-4","volume":"64","author":"HE de Vries","year":"1996","unstructured":"de Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ, Breimer DD, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37\u201343.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"726_CR51","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/32.10.6090533","volume":"32","author":"AW Krause","year":"1984","unstructured":"Krause AW, Carley WW, Webb WW. Fluorescent erythrosin B is preferable to Trypan blue as a vital exclusion dye for mammalian cells in monolayer culture. J Histochem Cytochem. 1984;32(10):1084\u201390.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"726_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12987-024-00519-7","volume":"21","author":"Y Hu","year":"2024","unstructured":"Hu Y, Girdenyt\u00e9 M, Roest L, Liukkonen I, Siskou M, B\u00e4llgren F, et al. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids Barriers CNS. 2024;21(1):13.","journal-title":"Fluids Barriers CNS"},{"issue":"12","key":"726_CR53","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1021\/acs.molpharmaceut.7b00480","volume":"14","author":"I Loryan","year":"2017","unstructured":"Loryan I, Hoppe E, Hansen K, Held F, Kless A, Linz K, et al. Quantitative assessment of drug delivery to tissues and association with phospholipidosis: A case study with two structurally related diamines in development. Mol Pharm. 2017;14(12):4362\u201373.","journal-title":"Mol Pharm"},{"issue":"9","key":"726_CR54","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/jps.20893","volume":"96","author":"HE Hassan","year":"2007","unstructured":"Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel\u2019s tissue distribution in Sprague Dawley rats. J Pharm Sci. 2007;96(9):2494\u2013506.","journal-title":"J Pharm Sci"},{"issue":"1","key":"726_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/dmd.109.029199","volume":"38","author":"HE Hassan","year":"2010","unstructured":"Hassan HE, Myers AL, Lee IJ, Chen H, Coop A, Eddington ND. Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis. Drug Metab Dispos. 2010;38(1):157\u201367.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"726_CR56","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.2174\/1570159X15666170504095823","volume":"15","author":"C Chaves","year":"2017","unstructured":"Chaves C, Remiao F, Cisternino S, Decleves X. Opioids and the Blood-Brain barrier: A dynamic interaction with consequences on drug disposition in brain. Curr Neuropharmacol. 2017;15(8):1156\u201373.","journal-title":"Curr Neuropharmacol"},{"issue":"2\u20133","key":"726_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0169-409X(98)00083-0","volume":"36","author":"R Cecchelli","year":"1999","unstructured":"Cecchelli R, Dehouck B, Descamps L, Fenart L, Bu\u00e9e-Scherrer VV, Duhem C, et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev. 1999;36(2\u20133):165\u201378.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"726_CR58","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1152\/jappl.1987.62.3.1076","volume":"62","author":"JA Cooper","year":"1987","unstructured":"Cooper JA, Del Vecchio PJ, Minnear FL, Burhop KE, Selig WM, Garcia JG, et al. Measurement of albumin permeability across endothelial monolayers in vitro. J Appl Physiol (1985). 1987;62(3):1076\u201383.","journal-title":"J Appl Physiol (1985)"},{"key":"726_CR59","doi-asserted-by":"crossref","unstructured":"Melander E, Eriksson C, Wellens S, Hosseini K, Fredriksson R, Gosselet F, et al. Differential blood-brain barrier transport and cell uptake of cyclic peptides in vivo and in vitro. Pharmaceutics. 2023;15(5).","DOI":"10.3390\/pharmaceutics15051507"},{"issue":"2","key":"726_CR60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2211068214561025","volume":"20","author":"B Srinivasan","year":"2015","unstructured":"Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. TEER measurement techniques for in vitro barrier model systems. J Lab Autom. 2015;20(2):107\u201326.","journal-title":"J Lab Autom"},{"key":"726_CR61","doi-asserted-by":"crossref","unstructured":"Shamul JG, Wang Z, Gong H, Ou W, White AM, Moniz-Garcia DP, et al. Meta-analysis of the make-up and properties of in vitro models of the healthy and diseased blood\u2013brain barrier. Nat Biomedical Eng. 2024.","DOI":"10.1038\/s41551-024-01250-2"},{"issue":"9","key":"726_CR62","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1002\/jps.22567","volume":"100","author":"MW Sadiq","year":"2011","unstructured":"Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, et al. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci. 2011;100(9):3912\u201323.","journal-title":"J Pharm Sci"},{"key":"726_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.brainres.2010.07.077","volume":"1354","author":"E Fasler-Kan","year":"2010","unstructured":"Fasler-Kan E, Suenderhauf C, Barteneva N, Poller B, Gygax D, Huwyler J. Cytokine signaling in the human brain capillary endothelial cell line hCMEC\/D3. Brain Res. 2010;1354:15\u201322.","journal-title":"Brain Res"},{"issue":"33","key":"726_CR64","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.2174\/138161211798220918","volume":"17","author":"W Pan","year":"2011","unstructured":"Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. Curr Pharm Design. 2011;17(33):3729\u201340.","journal-title":"Curr Pharm Design"},{"issue":"2","key":"726_CR65","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1124\/pr.107.07109","volume":"60","author":"DS Miller","year":"2008","unstructured":"Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60(2):196\u2013209.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"726_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10571-009-9431-1","volume":"30","author":"B Poller","year":"2010","unstructured":"Poller B, Drewe J, Kr\u00e4henb\u00fchl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol. 2010;30(1):63\u201370.","journal-title":"Cell Mol Neurobiol"},{"key":"726_CR67","doi-asserted-by":"publisher","first-page":"146647","DOI":"10.1016\/j.brainres.2020.146647","volume":"1730","author":"AC Voirin","year":"2020","unstructured":"Voirin AC, Perek N, Roche F. Inflammatory stress induced by a combination of cytokines (IL-6, IL-17, TNF-\u03b1) leads to a loss of integrity on bEnd.3 endothelial cells in vitro BBB model. Brain Res. 2020;1730:146647.","journal-title":"Brain Res"},{"issue":"2","key":"726_CR68","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/0271678X18822801","volume":"40","author":"Y Hoshi","year":"2020","unstructured":"Hoshi Y, Uchida Y, Tachikawa M, Ohtsuki S, Couraud PO, Suzuki T, et al. Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier. J Cereb Blood Flow Metab. 2020;40(2):420\u201336.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"726_CR69","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0022-5347(25)00388-X","volume":"240","author":"MJ Goldberg","year":"1987","unstructured":"Goldberg MJ, Spector R, Chiang CK. Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther. 1987;240(3):717\u201322.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"726_CR70","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/fcp.12596","volume":"35","author":"F Simon","year":"2021","unstructured":"Simon F, Guyot L, Garcia J, Vilchez G, Bardel C, Chenel M, et al. Impact of interleukin-6 on drug transporters and permeability in the hCMEC\/D3 blood-brain barrier model. Fundam Clin Pharmacol. 2021;35(2):397\u2013409.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"726_CR71","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41598-019-41828-4","volume":"9","author":"S Gustafsson","year":"2019","unstructured":"Gustafsson S, Sehlin D, Lampa E, Hammarlund-Udenaes M, Loryan I. Heterogeneous drug tissue binding in brain regions of rats, alzheimer\u2019s patients and controls: impact on translational drug development. Sci Rep. 2019;9(1):5308.","journal-title":"Sci Rep"},{"key":"726_CR72","doi-asserted-by":"publisher","first-page":"43047","DOI":"10.1038\/srep43047","volume":"7","author":"A Mateus","year":"2017","unstructured":"Mateus A, Treyer A, Wegler C, Karlgren M, Matsson P, Artursson P. Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Sci Rep. 2017;7:43047.","journal-title":"Sci Rep"},{"key":"726_CR73","doi-asserted-by":"crossref","unstructured":"Gillen CM, Forbush B 3. Functional interaction of the K-Cl cotransporter (KCC1) with the Na-K-Cl cotransporter in HEK-293 cells. Am J Physiol. 1999;276(2):C328\u201336.","DOI":"10.1152\/ajpcell.1999.276.2.C328"},{"issue":"3","key":"726_CR74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/dmd.110.035998","volume":"39","author":"M Frid\u00e9n","year":"2011","unstructured":"Frid\u00e9n M, Bergstr\u00f6m F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353\u201362.","journal-title":"Drug Metab Dispos"},{"key":"726_CR75","doi-asserted-by":"crossref","unstructured":"B\u00e4llgren F, Hu Y, Van De Li S, Hammarlund-Udenaes M, Loryan I. Region-independent active CNS net uptake of marketed H+\/OC antiporter system substrates. Front Cell Neurosci. 2024;18.","DOI":"10.3389\/fncel.2024.1493644"},{"key":"726_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1124\/dmd.123.001354","volume":"52","author":"S Akino","year":"2023","unstructured":"Akino S, Yasujima T, Shibutani R, Yamashiro T, Yuasa H. Involvement of proton-coupled SLC49A4-mediated transport in the export of lysosomally trapped pyrilamine. Drug Metab Dispos. 2023;52:19\u201325.","journal-title":"Drug Metab Dispos"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-025-00726-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:17:51Z","timestamp":1781612271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-025-00726-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s12987-025-00726-w","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rodents used for isolation of primary BEC experiments were conducted in compliance with guidelines established by Danish Animal Welfare Act. Isolation of BECs from pigs were performed using brains as byproducts of the Danish food industry, from local slaughterhouses operating in accordance with the Danish Ministry of Environment and Food. Rat brains used for microdialysis, brain slice, and equilibrium dialysis experiments were conducted in compliance with the guidelines established by the Swedish National Board for Laboratory Animals and received approval from the Animal Ethics Committee of Uppsala, Sweden (5.8.18\u201312230\/2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}